Sonnet Operating Income from 2010 to 2024
| SONN Stock | USD 1.61 0.11 6.40% |
Operating Income | First Reported 2006-09-30 | Previous Quarter -3.9 M | Current Value -3.5 M | Quarterly Volatility 3.3 M |
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 5.12. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
Sonnet | Operating Income |
Latest Sonnet Biotherapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Sonnet Biotherapeutics Holdings over the last few years. Operating Income is the amount of profit realized from Sonnet Biotherapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Sonnet Biotherapeutics Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Sonnet Biotherapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Sonnet Operating Income Regression Statistics
| Arithmetic Mean | (8,470,972) | |
| Coefficient Of Variation | (105.10) | |
| Mean Deviation | 6,820,459 | |
| Median | (4,943,755) | |
| Standard Deviation | 8,903,190 | |
| Sample Variance | 79.3T | |
| Range | 28.6M | |
| R-Value | (0.46) | |
| Mean Square Error | 67.3T | |
| R-Squared | 0.21 | |
| Significance | 0.08 | |
| Slope | (914,937) | |
| Total Sum of Squares | 1109.7T |
Sonnet Operating Income History
Other Fundumenentals of Sonnet Biotherapeutics
Sonnet Biotherapeutics Operating Income component correlations
Click cells to compare fundamentals
About Sonnet Biotherapeutics Financial Statements
Sonnet Biotherapeutics investors utilize fundamental indicators, such as Operating Income, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -4.7 M | -4.9 M | |
| Non Operating Income Net Other | -556.1 K | -528.3 K |
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.